Figure 1.
Efficacy of secukinumab 150 mg (A) and secukinumab 300 mg (B) in patients with moderate-to-severe plaque psoriasis over 24 weeks of treatment. The PASI 75, PASI 90, and PASI 100 response rates were evaluated at weeks 5, 12, 16, and 24. PASI: Psoriasis area and severity index.